National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Dupilumab (Dupixent®) is indicated for treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.

NCPE Assessment Process Ongoing
Rapid review commissioned 13/11/2017
Rapid review completed 24/11/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended
Full pharmacoeconomic assessment commissioned by the HSE 29/11/2017
Pre-submission consultation with Applicant 18/06/2018
Submission received from Applicant 25/03/2019
Preliminary review sent to Applicant 05/06/2019
NCPE assessment re-commenced 01/07/2019
Factual accuracy sent to Applicant 08/11/2019
NCPE assessment re-commenced 22/11/2019
Current Status NCPE assessment ongoing